The authors investigate the efficacy of hrR3, a viral vector derived from herpes simplex virus type 1 (HSV 1), in destroying colon carcinoma cells in vitro and in vivo. The effect of adding the prodrug ganciclovir in combination with hrR3 infection also is assessed.
Objective
The authors investigate the efficacy of hrR3, a viral vector derived from herpes simplex virus type 1 (HSV 1), in destroying colon carcinoma cells in vitro and in vivo. The effect of adding the prodrug ganciclovir in combination with hrR3 infection also is assessed.
Summary Background Data
Most cancer gene therapy strategies use viral vectors that are incapable of replication. The HSV 1 vector hrR3 is capable of replication, and its replication is cytotoxic to cells. hrR3 also possesses the HSV-thymidine kinase gene, which converts ganciclovir into a toxic metabolite. Thus, the addition of ganciclovir to hrR3-infected cells may enhance the ability of hrR3 to destroy tumor cells. To increase specificity for tumor cells, hrR3 has a mutated ribonucleotide reductase gene and replicates selectively in cells with high levels of endogenous ribonucleotide reductase. Actively dividing cells such as tumor cells have high levels of endogenous ribonucleotide reductase for synthesis of DNA precursors. The authors are interested in the use of HSV 1 vectors to treat liver metastases from colorectal cancer.
Methods
Ribonucleotide reductase expression in several colon carcinoma cell lines and in primary cultures of human hepatocytes was determined by Western blot analysis. hrR3-mediated cytotoxicity in the colon carcinoma cell lines was determined using an in vitro assay. The human colon carcinoma cell line HT29 was injected into the flanks of nude mice followed by intratumoral injection of hrR3. Tumor growth rate was assessed with and without the addition of intraperitoneal ganciclovir.
Results
Ribonucleotide reductase levels in colon carcinoma cell lines are much higher than in primary cultures of human hepatocytes. hrR3 efficiently destroys colon carcinoma cell lines in vitro. A single intratumoral injection of hrR3 into HT29 flank tumors significantly reduces tumor growth rate, and the administration of ganciclovir has no additive effect.
Conclusions
The inherent cytotoxicity of hrR3 replication effectively destroys colon carcinoma cells in vitro and in vivo. This cytotoxicity is not enhanced in vivo by the addition of ganciclovir. In the future, more efficacious and selective HSV 1 Twelve mice were used in each of the four groups.
Liver Sections and Histochemical Staining
Additional mice were subjected to the same protocol of tumor inoculation in the flank followed by intratumoral hrR3 injection, except that intratumoral hrR3 injection was performed on PTD 7 and repeated on PTD 10 and PTD 13. On PTD 14 and 54, the mice were killed, and tumor, liver, and brain specimens were obtained. Specifically, metofane inhalational anesthesia was administered, the inferior vena cava was lacerated, and PBS was administered by intracardiac injection followed by 3% paraformaldehyde in PBS. Tumor and liver specimens were dissected, soaked in 3% paraformaldehyde for 1 to 2 hours, washed with PBS, soaked in 30% sucrose for 24 to 48 hours, and snap-frozen in OCT Compound (Miles, Elkhart, IN) in liquid nitrogen. Brain specimens were treated similarly except that they were fixed in 3% paraformaldehyde for 24 hours. Five AM sections were cut on a cryostat and placed onto slides. Slides were washed with PBS, incubated for 24 to 48 hours in a solution containing 1 mg/ml 5-bromo-4-chloro-3-indolylbeta-D-galactopyranoside (X-gal, Sigma Chemical Co.), 5 mM potassium ferricyanide, 5 (Fig. 3A) . By 28 days after HT29 injection, the percentage tumor growth of treated tumors was 857%, whereas the percentage tumor growth of untreated controls was 2033% (p = 0.0033). Neither of these two groups of mice received ganciclovir. The addition of intraperitoneal ganciclovir to mice treated with an intratumoral injection of hrR3 or HBSS had no effect on tumor growth (Fig. 3B) . There was no observed toxicity in hrR3-treated mice during this period.
Histochemical Staining of Tumors hrR3 possesses the E. coli lacZ gene, enabling detection of hrR3-infected cells by histochemical staining for lacZ expression. As seen in Figure 4A , tumors stained for lacZ expression 1 day after the last of three intratumoral injections of hrR3 show intense blue staining throughout much of the tumor. Grossly, more than 75% of the tumor sections stained positively for lacZ expression. At 41 days after the last intratumoral injection of hrR3, only small islands of blue-staining cells were observed, with one such island shown in Figure 4B . Grossly, less than 10% of the tumor sections stained positively for lacZ expression. Staining of brain and liver specimens from these mice revealed no lacZ expression (data not shown). Figure 3A demonstrates the tumor growth curves for mice receiving saline followed by intraperitoneal PBS (no virus/PBS) and mice receiving hrR3 followed by intraperitoneal PBS (hrR3/PBS). In Figure 3B , two tumor growth curves have been added to the curves from Figure 3A , the tumor growth curve for mice receiving saline followed by intraperitoneal GCV (no virus/GC\) and mice receiving hrR3 followed by intraperitoneal GCV (hrR3/GCV). Standard 
